特拉斯图祖马布德鲁克斯泰康治疗 HER2 阳性乳腺癌与中枢神经系统转移
Hiroaki Yamane1,2, Tomoko Itagaki1, Keiko Kajitani1
1Department of Breast Surgery, Hiroshima General Hospital, Hiroshima, Japan.
Case reports in oncology
|February 21, 2025
概括
特拉斯图祖马布德鲁克斯坦 (T-DXd) 在治疗HER2阳性乳腺癌患者的脑转移 (BM) 和罕见的脊髓转移方面表现有前途. 两位患者都经历了瘤减少,并与T-DXd治疗保持了部分反应.
科学领域:
- 在瘤学瘤学.
- 医学研究 医学研究
背景情况:
- 中枢神经系统 (CNS) 转移在HER2阳性乳腺癌中很常见,显著影响预后和生活质量.
- 脊髓转移是罕见的,缺乏标准化的治疗方案.
- 在临床试验中,Trastuzumab deruxtecan (T-DXd) 证明了对大脑转移 (BM) 的有效性.
研究的目的:
- 报告T-DXd治疗结果在患有HER2阳性乳腺癌转移到中枢神经系统的患者中,包括罕见的骨髓内脊髓转移 (ISCM).
- 评估T-DXd在控制复杂中枢神经系统转移中的疗效和安全性.
主要方法:
- 两名患有HER2阳性乳腺癌和中枢神经系统转移的患者的病例报告.
- 患者1:接受T-DXd治疗,作为治疗多重骨和ISCM的第四线疗法.
- 患者2:接受T-DXd治疗,作为对多种BM和其他转移部位的二线治疗.
主要成果:
- 患者1实现了部分反应,减少了BM和ISCM,维持了12个月;只经历了1级疲劳.
- 患者2获得了部分反应与BMs的收缩,维持了6个月;初级和其他转移显示稳定.
- 在T-DXd的研究中,T-DXd证明了对BM和ISCM的治疗效果.
结论:
- 在HER2阳性乳腺癌中,T-DXd显示了中枢神经系统转移的治疗潜力,包括罕见的ISCM.
- 药物穿越血脑屏障的能力有助于其对抗BMs的有效性.
- 积极的结果表明T-DXd是挑战中枢神经系统转移性疾病的可行治疗选择.
更多相关视频
13:59High-Content Screening Assay for the Identification of Antibody-Dependent Cellular Cytotoxicity Modifying Compounds
Published on: August 18, 2023
1.9K
13:19Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery
Published on: April 26, 2024
2.5K
相关概念视频
02:57Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
01:28Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
147
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
147
01:27Tumor Immunotherapy
463
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
463